Microgynon 30

Ethinylestradiol, the active ingredient in Microgynon 30, is a combined oral contraceptive presented as a 30 µg/150 µg tablet for oral use. It works together with levonorgestrel to prevent pregnancy in women of reproductive age.

GNH USA supplies Microgynon 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and offering reliable logistics for timely delivery.

Microgynon 30, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

- Contraception: Prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus. - Menstrual cycle regulation: Helps achieve more regular bleeding patterns and reduces heavy flow. - Dysmenorrhea relief: May lessen menstrual pain associated with ovulatory cycles.

Microgynon 30 may cause a range of adverse reactions. Most are mild and transient, but serious events can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like. - Breast tenderness: discomfort or swelling of the breasts. - Irregular bleeding: spotting or breakthrough bleeding between periods.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to the lungs. - Severe allergic reaction: hives, swelling, or anaphylaxis.

Before prescribing Microgynon 30, clinicians should consider several safety factors.

- Assess thrombotic risk: evaluate personal or family history of clotting disorders. - Avoid smoking: especially in women older than 35 years. - Monitor blood pressure: hypertension may increase cardiovascular risk. - Consider liver function: hepatic disease can alter hormone metabolism. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Microgynon 30 can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): reduce contraceptive effectiveness. - Rifampin and similar antibiotics: may lower hormone levels. - Protease inhibitor antiretrovirals (e.g., ritonavir): can increase hormone concentrations and side‑effect risk.

Moderate Interactions (Monitor Closely): - St. John’s wort: may decrease contraceptive efficacy. - Certain antifungals (e.g., ketoconazole): may raise hormone levels, requiring monitoring.